Sleep Disorders and Gastroesophageal Reflux Disease (GERD)

The Impact of Gastroesophageal Reflux Disease in Sleep Disorders: A Pilot Investigation of Rabeprazole, 20 mg Twice Daily for the Relief of GERD-Related Insomnia.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00287391

Enrollment

Registered

2006-02-06

Start date

2004-09-30

Completion date

2006-12-31

Last updated

2007-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GERD, Insomnia

Keywords

Insomnia, Gastroesophageal Reflux Disease (GERD), Sleep Disturbance

Brief summary

This study will investigate Gastroesophageal Reflux Disease (GERD)as a cause of sleep disturbance. Patients with GERD may experience all or some of the following symptoms: stomach acid or partially digested food re-entering the esophagus (which is sometimes referred to as heartburn or regurgitation) and belching. Even very small, unnoticeable amounts of rising stomach acid may cause patients to wake up during the night. This study will also investigate the effect of Rabeprazole, (brand name Aciphex) on patients with known insomnia. Rabeprazole is an FDA approved medication already marketed for the treatment of GERD.

Detailed description

Participants with known insomnia will undergo an overnight pH and sleep study. Those found to be eligible after the first sleep study (those with significantly poor sleep quality and no significant sleep apnea) will be started on 2 weeks 20 mgs, twice-a-day, rabeprazole. Upon completion of the 2 week course of rabeprazole, subjects will repeat the overnight pH and sleep studies. Upon completion of these studies, participation is complete.

Interventions

DRUGRabeprazole

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

1. English-speaking male or female subjects, 18-75 years of age. (Women must be two (2) years post-menopausal or surgically sterile. Women of childbearing potential or \<1 year post-menopausal must be practicing an approved method of contraception and have a negative urine pregnancy test at screening.), 2. a six-month duration of insomnia, 3. sleep difficulty at least 3 nights per week, and a sleep study demonstrating \> 10 arousals/hour for those aged \< 45, and \>15 for those who are 45 or older.

Exclusion criteria

1. BMI \> 30 or history of snoring (in order to decrease the prevalence of sleep apnea in the sample), 2. use of any proton pump inhibitor or H2 receptor antagonist within one week of undergoing initial sleep study, 3. previous acid-suppressing medication for sleep disturbances, 4. previous surgical antireflux procedure, 5. current medical therapy that includes digoxin or ketoconazole, 6. previous aerodigestive malignancy, 7. a previously diagnosed psychological or medical cause of insomnia (other than suspected GERD), and 8. inability or unwillingness to provide consent for the procedures.

Design outcomes

Primary

Measure	Time frame
The percentage of: subjects with non-OSA sleep disturbances who demonstrate esophageal reflux, night-time arousals which are accompanied by a reflux event.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026